Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Nihon Nohyaku Co., Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, providing a variety of perspectives on the company's pharmaceutical claims. Both matters are housed within 1 distinct art unit, ensuring a consistent technical environment for prosecution. The concentration in 1 distinct art unit suggests that the company's current legal challenges are focused within a specific regulatory or technical niche of the biotechnology sector. Practitioners can leverage this consistency to develop a unified technical narrative for the art unit.
The busiest examiner, MARTIN, KEVIN STEPHEN, is currently handling 1 pending office action. Since there are 2 distinct examiners for the 2 pending actions, the workload is perfectly distributed. This arrangement means that the 2 pending office actions are reviewed by different individuals, even though they share the same 1 distinct art unit. Practitioners should tailor arguments to the 2 distinct examiners while maintaining technical consistency for the art unit. The 2 pending office actions represent a focused effort to secure intellectual property through multiple channels of review. This structure allows for independent evaluations of the company's pharmaceutical innovations within a stable procedural framework.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.2% | +23.2% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566534 | BENZIMIDAZOLE COMPOUND OR SALT THEREOF, CANINE FILARIASIS CONTROL AGENT CONTAINING SAME, AND METHOD OF USE THEREOF | SHOWALTER, ALEXANDER KEITH | 9d |
| 18845166 | PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | MARTIN, KEVIN STEPHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566534 | BENZIMIDAZOLE COMPOUND OR SALT THEREOF, CANINE FILARIASIS CONTROL AGENT CONTAINING SAME, AND METHOD OF USE THEREOF | SHOWALTER, ALEXANDER KEITH | 9d |
| 18845166 | PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18845166 | PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | MARTIN, KEVIN STEPHEN | — | §101§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18566534 | BENZIMIDAZOLE COMPOUND OR SALT THEREOF, CANINE FILARIASIS CONTROL AGENT CONTAINING SAME, AND METHOD OF USE THEREOF | SHOWALTER, ALEXANDER KEITH | 1629 | §102§112 | Non-Final OA | 9d | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial